2019 A Boom Year for UK Biotech, Despite Brexit Concerns
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
Address: Unit 6 Regents Drive,
Low Prudhoe Industrial Estate, Northumberland.
NE42 6PX.,United Kingdom
Tel: +44 (0) 1661 833 693
Web: www.scmpharma.com
SCM Pharma is a UK-based contract development and manufacturing organisation (CDMO) that develops and delivers novel, difficult and dangerous drugs on behalf of its clients. The company works with clients progressing drugs through the pre-clinical formulation stage, clinical trials and others that require low volume commercial supply of niche licensed products.
Privately-owned, SCM Pharma’s corporate HQ and MHRA-licensed manufacturing facilities are located in North East England with recently acquired additional laboratory space within the University of Sunderland’s state-of-the-art £8.5m science complex. Its clients include top 10 big pharma, speciality pharmaceutical companies, small biotech firms, virtual companies, public sector bodies and academic institutions from across Europe and North America.
With specific expertise in custom formulation, complex cGMP sterile manufacturing and aseptic filling, the award-winning CDMO is able to handle 14C radiolabeled compounds and potent products including cytotoxics. Its specialist offerings include –
• Process development
• Formulation development
• Aseptic processing (using isolator technology)
• Non-aseptic processing followed by terminal sterilisation
• GMP filling of 14C radiolabeled compounds
• Fill/¬finish of highly potent products including cytotoxic and cytostatic formulations
• Drug/medical device fi¬lling and assembly
• In-house testing including sterility, endotoxin, microbiology and analytical chemistry
• ICH stability testing
• Clinical packaging and distribution
• QP release
SCM Pharma can fill liquids, gels and powders into a range of final dosage forms including ampoules, vials, cartridges, syringes, bottles.
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial asset on the market, a strong pipeline of development assets and a…
Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
The 9th February 2019 marked the launch of the European Medicines Verification System (EMVS) which will use cutting-edge technology to safeguard the medicine supply chain against fake products. Each European country…
In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were becoming immune to these warnings, the UK has…
An unusual characteristic of the UK’s healthcare landscape is that charities fund the vast majority of medical research. According to the Association of Medical Research Charities (AMRC), in 2017, 8 million people…
The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products…
Ian Chamberlain looks at the changing role of the pharma sales manager and the skills needed to keep up with new tech and the next generation of millennial sales reps. With…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In his second piece for PharmaBoardroom, Aditya examines the dangers of nationalism and populism for the private sector. The biggest global risk I see…
With more than 25 years pharmaceutical industry experience, Ian Chamberlain provides training to help pharma salespeople talk to customers and provides sales managers with software to help pharma companies intelligently listen…
See our Cookie Privacy Policy Here
